# Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis

> **NCT07239102** · — · COMPLETED · sponsor: **Beijing Tiantan Hospital** · enrollment: 300 (actual)

## Conditions studied

- EGFR Positive Non-small Cell Lung Cancer
- Central Nervous System Metastasis
- Leptomeningeal Metastasis

## Interventions

- **DRUG:** Firmonertinib

## Key facts

- **NCT ID:** NCT07239102
- **Lead sponsor:** Beijing Tiantan Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-10-01
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07239102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07239102, "Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07239102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*